Novartis Ag (NVSEF) Other Non-Current Liabilities (2009 - 2026)

Novartis Ag has disclosed Other Non-Current Liabilities across 15 years of filings, most recently posting -$100.0 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at -$100.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$100.0 million (changed N/A YoY), and the FY2025 annual result was $4.1 billion, up 1.42% from the prior year.
• Other Non-Current Liabilities came in at -$100.0 million for Q1 2026 at Novartis Ag, down from $4.1 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $5.4 billion in Q2 2022 to a low of -$100.0 million in Q1 2026.
• The 5-year median for Other Non-Current Liabilities is $4.1 billion (2025), against an average of $3.2 billion.
• Across the five-year window, Other Non-Current Liabilities retreated 14.93% in 2022 and jumped 406.84% in 2024, its largest moves.
• Novartis Ag's Other Non-Current Liabilities stood at $874.0 million in 2022, then dropped by 8.01% to $804.0 million in 2023, then surged by 406.84% to $4.1 billion in 2024, then gained by 1.42% to $4.1 billion in 2025, then sank by 102.42% to -$100.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at -$100.0 million (Q1 2026), $4.1 billion (Q4 2025), and $4.2 billion (Q2 2025), per Business Quant data.